SEC Hints At Further Charges In Bristol Case
This article was originally published in The Pink Sheet Daily
The Securities & Exchange Commission's continuing investigation into Bristol-Myers Squibb's inventory accounting practices includes potential charges against "individuals responsible for the company's failures.
You may also be interested in...
Former Bristol-Myers Squibb CFO Fred Schiff and former Worldwide Medicines Group President Richard Lane face charges of securities fraud and conspiracy to commit securities fraud in connection with the Department of Justice investigation of Bristol's "channel stuffing" practices
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.